{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:09:05Z","timestamp":1789834145607,"version":"4.0.1"},"reference-count":151,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01481-3","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T14:56:53Z","timestamp":1780066613000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardiotoxicity induced by multiple myeloma therapies: mechanistic convergence across proteasome inhibitors, CAR-T, and bispecific antibodies"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3038-9568","authenticated-orcid":false,"given":"Arnav Ramnath","family":"Chatrathi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8894-027X","authenticated-orcid":false,"given":"Krina","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas L.","family":"Palaskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"1481_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2174\/1871529X21666210412113017","volume":"21","author":"A Latif","year":"2021","unstructured":"Latif A, Kapoor V, Lateef N, Ahsan MJ, Usman RM, Malik SU, et al. Incidence and management of carfilzomib-induced cardiovascular toxicity; a systematic review and meta-analysis. Cardiovasc Hematol Disord-Drug Targets. 2021;21:30\u201345.","journal-title":"Cardiovasc Hematol Disord-Drug Targets"},{"key":"1481_CR2","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1182\/bloodadvances.2017015545","volume":"2","author":"A Chari","year":"2018","unstructured":"Chari A, Stewart AK, Russell SD, Moreau P, Herrmann J, Banchs J, et al. Analysis of carfilzomib cardiovascular safety profile across relapsed and\/or refractory multiple myeloma clinical trials. Blood Adv. 2018;2:1633\u201344. https:\/\/doi.org\/10.1182\/bloodadvances.2017015545.","journal-title":"Blood Adv"},{"key":"1481_CR3","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1182\/blood-2019-127987","volume":"134","author":"MA Mendez-Lopez","year":"2019","unstructured":"Mendez-Lopez MA, Besse A, Florea B, Zuppinger C, Overkleeft H, Driessen C, et al. Carfilzomib induces cardiotoxicity via \u00df5\/\u00df2-specific proteasome subunit inhibition pattern. Blood. 2019;134:3110. https:\/\/doi.org\/10.1182\/blood-2019-127987.","journal-title":"Blood"},{"key":"1481_CR4","doi-asserted-by":"publisher","first-page":"e174519","DOI":"10.1001\/jamaoncol.2017.4519","volume":"4","author":"AJ Waxman","year":"2018","unstructured":"Waxman AJ, Clasen S, Hwang WT, Garfall A, Vogl DT, Carver J, et al. Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol. 2018;4:e174519. https:\/\/doi.org\/10.1001\/jamaoncol.2017.4519.","journal-title":"JAMA Oncol"},{"key":"1481_CR5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/cam4.3568","volume":"10","author":"R Bishnoi","year":"2021","unstructured":"Bishnoi R, Xie Z, Shah C, Bian J, Murthy HS, Wingard JR, et al. Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-medicare data set analysis. Cancer Med. 2021;10:70\u20138. https:\/\/doi.org\/10.1002\/cam4.3568.","journal-title":"Cancer Med"},{"key":"1481_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.645678","volume":"8","author":"G Mingrone","year":"2021","unstructured":"Mingrone G, Astarita A, Airale L, Maffei I, Cesareo M, Crea T, et al. Effects of carfilzomib therapy on left ventricular function in multiple myeloma patients. Front Cardiovasc Med. 2021;8:645678. https:\/\/doi.org\/10.3389\/fcvm.2021.645678.","journal-title":"Front Cardiovasc Med"},{"key":"1481_CR7","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.3390\/cancers13071631","volume":"13","author":"A Astarita","year":"2021","unstructured":"Astarita A, Mingrone G, Airale L, Vallelonga F, Covella M, Catarinella C, et al. Multiple myeloma patients undergoing carfilzomib: development and validation of a risk score for cardiovascular adverse events prediction. Cancers. 2021;13:1631. https:\/\/doi.org\/10.3390\/cancers13071631.","journal-title":"Cancers"},{"key":"1481_CR8","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1200\/JCO.19.00231","volume":"37","author":"RF Cornell","year":"2019","unstructured":"Cornell RF, Ky B, Weiss BM, Dahm CN, Gupta DK, Du L, et al. Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma. J Clin Oncol. 2019;37:1946\u201355. https:\/\/doi.org\/10.1200\/JCO.19.00231.","journal-title":"J Clin Oncol"},{"key":"1481_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40959-017-0023-9","volume":"3","author":"JH Chen","year":"2017","unstructured":"Chen JH, Lenihan DJ, Phillips SE, Harrell SL, Cornell RF. Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma. Cardio-Oncol. 2017;3:4. https:\/\/doi.org\/10.1186\/s40959-017-0023-9.","journal-title":"Cardio-Oncol"},{"key":"1481_CR10","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1182\/blood.V126.23.5363.5363","volume":"126","author":"JH Chen","year":"2015","unstructured":"Chen JH, Lenihan DJ, Phillips SE, Jagasia MH, Goodman SA, Kassim AA, et al. Risk factors for cardiac toxicities associated with proteasome inhibitor chemotherapy during treatment of multiple myeloma. Blood. 2015;126:5363 https:\/\/doi.org\/10.1182\/blood.V126.23.5363.5363.","journal-title":"Blood"},{"key":"1481_CR11","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1182\/blood.V128.22.4491.4491","volume":"128","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Roussou M, Gavriatopoulou M, Psimenou E, Ziogas D, Eleutherakis-Papaiakovou E, et al. Cardiac and renal complications of carfilzomib therapy in patients with multiple myeloma. Blood. 2016;128:4491 https:\/\/doi.org\/10.1182\/blood.V128.22.4491.4491.","journal-title":"Blood"},{"key":"1481_CR12","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1182\/bloodadvances.2023009766","volume":"7","author":"DH Lee","year":"2023","unstructured":"Lee DH, Kumar A, Mohammed T, Peres LC, Alsina M, Bachmeier C, et al. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma. Blood Adv. 2023;7:4247\u201357. https:\/\/doi.org\/10.1182\/bloodadvances.2023009766.","journal-title":"Blood Adv"},{"key":"1481_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.691064","volume":"11","author":"K Qi","year":"2021","unstructured":"Qi K, Yan Z, Cheng H, Chen W, Wang Y, Wang X, et al. An analysis of cardiac disorders associated with chimeric antigen receptor T cell therapy in 126 patients: a single-centre retrospective study. Front Oncol. 2021;11:691064. https:\/\/doi.org\/10.3389\/fonc.2021.691064.","journal-title":"Front Oncol"},{"key":"1481_CR14","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","volume":"74","author":"RM Alvi","year":"2019","unstructured":"Alvi RM, Frigault MJ, Fradley MG, Jain MD, Mahmood SS, Awadalla M, et al. Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). J Am Coll Cardiol. 2019;74:3099\u2013108. https:\/\/doi.org\/10.1016\/j.jacc.2019.10.038.","journal-title":"J Am Coll Cardiol"},{"key":"1481_CR15","doi-asserted-by":"publisher","first-page":"e008518","DOI":"10.1136\/jitc-2023-008518","volume":"12","author":"A Sayed","year":"2024","unstructured":"Sayed A, Munir M, Ghazi SM, Ferdousi M, Krishan S, Shaaban A, et al. Cardiovascular toxicities associated with bispecific T-cell engager therapy. J Immunother Cancer. 2024;12:e008518. https:\/\/doi.org\/10.1136\/jitc-2023-008518.","journal-title":"J Immunother Cancer"},{"key":"1481_CR16","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/nejmoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316. https:\/\/doi.org\/10.1056\/nejmoa2024850.","journal-title":"N Engl J Med"},{"key":"1481_CR17","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/jco.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, et al. Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium. J Clin Oncol. 2023;41:2087\u201397. https:\/\/doi.org\/10.1200\/jco.22.01365.","journal-title":"J Clin Oncol"},{"key":"1481_CR18","doi-asserted-by":"publisher","first-page":"7232","DOI":"10.1182\/blood-2024-210189","volume":"144","author":"N Tabbara","year":"2024","unstructured":"Tabbara N, Singel M, Allen N, Shedeck A, Mooney K, Campion K, et al. Use of baseline inflammatory markers to predict toxicities among relapsed\/refractory multiple myeloma patients receiving ambulatory teclistamab and talquetamab. Blood. 2024;144:7232. https:\/\/doi.org\/10.1182\/blood-2024-210189.","journal-title":"Blood"},{"key":"1481_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1132503","volume":"10","author":"S Sarfati","year":"2023","unstructured":"Sarfati S, Norbert ME, H\u00e9rault A, Giry M, Makk\u00e9 J, Grall M, et al. Case report: CAR-T cell therapy-induced cardiac tamponade. Front Cardiovasc Med. 2023;10:1132503. https:\/\/doi.org\/10.3389\/fcvm.2023.1132503.","journal-title":"Front Cardiovasc Med"},{"key":"1481_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0026-7","volume":"7","author":"T Jain","year":"2017","unstructured":"Jain T, Narayanasamy H, Mikhael J, Reeder CB, Bergsagel PL, Mayo A, et al. Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma. Blood Cancer J. 2017;7:642. https:\/\/doi.org\/10.1038\/s41408-017-0026-7.","journal-title":"Blood Cancer J"},{"key":"1481_CR21","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1182\/blood.V126.23.4265.4265","volume":"126","author":"J Land","year":"2015","unstructured":"Land J, Afifi S, Adel NG, Devlin S, Arora A, Lendvai N, et al. Incidence and management of proteasome inhibitor-related cardiotoxicity in multiple myeloma patients at memorial sloan kettering cancer center. Blood. 2015;126:4265 https:\/\/doi.org\/10.1182\/blood.V126.23.4265.4265.","journal-title":"Blood"},{"key":"1481_CR22","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3390\/cancers11050622","volume":"11","author":"G Bruno","year":"2019","unstructured":"Bruno G, Bringhen S, Maffei I, Iannaccone A, Crea T, Ravera A, et al. Cardiovascular organ damage and blood pressure levels predict adverse events in multiple myeloma patients undergoing carfilzomib therapy. Cancers. 2019;11:622. https:\/\/doi.org\/10.3390\/cancers11050622.","journal-title":"Cancers"},{"key":"1481_CR23","doi-asserted-by":"publisher","first-page":"A4114505","DOI":"10.1161\/circ.150.suppl_1.4114505","volume":"150","author":"S Palfi","year":"2024","unstructured":"Palfi S, Koelmeyer H, Alsina M, Baz R, Blue B, Corallo S, et al. Abstract 4114505: cardiovascular adverse events after Anti-BCMA CAR-T (Ide-Cel and Cilta-Cel) for relapsed\/ refractory multiple myeloma. Circulation. 2024;150:A4114505. https:\/\/doi.org\/10.1161\/circ.150.suppl_1.4114505.","journal-title":"Circulation"},{"key":"1481_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jeaa356.040","volume":"22","author":"G Mingrone","year":"2021","unstructured":"Mingrone G, Astarita A, Maffei I, Cesareo M, Airale L, Bruno G, et al. Echocardiographic systolic and diastolic function alterations in multiple myeloma patients treated with Carfilzomib. Eur Heart J Cardiovasc Imaging. 2021;22:jeaa356.040. https:\/\/doi.org\/10.1093\/ehjci\/jeaa356.040.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"1481_CR25","doi-asserted-by":"publisher","unstructured":"Chavda SJ, Pocock R, Cheesman S, Lee K, Dowling E, Marks DJB, et al. Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendations. Br J Haematol. 2020;190. https:\/\/doi.org\/10.1111\/bjh.16889","DOI":"10.1111\/bjh.16889"},{"key":"1481_CR26","doi-asserted-by":"publisher","first-page":"4748","DOI":"10.1182\/blood.V124.21.4748.4748","volume":"124","author":"AC Rosenthal","year":"2014","unstructured":"Rosenthal AC, Luthi J, Belohlavek M, Mookadam F, Mayo A, Fonseca R, et al. The cardiovascular impact of carfilzomib in multiple myeloma. Blood. 2014;124:4748. https:\/\/doi.org\/10.1182\/blood.V124.21.4748.4748.","journal-title":"Blood"},{"key":"1481_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01261-5","volume":"15","author":"S Palfi","year":"2025","unstructured":"Palfi S, Peres LC, Koelmeyer H, Alsina M, Baz RC, Blue BJ, et al. Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma. Blood Cancer J. 2025;15:63. https:\/\/doi.org\/10.1038\/s41408-025-01261-5.","journal-title":"Blood Cancer J"},{"key":"1481_CR28","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"The Allhat Officers And Coordinators For The Allhat Collaborative Research Group.","year":"2002","unstructured":"The Allhat Officers And Coordinators For The Allhat Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288:2981\u201397. https:\/\/doi.org\/10.1001\/jama.288.23.2981.","journal-title":"JAMA"},{"key":"1481_CR29","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1182\/blood.2021011898","volume":"138","author":"DA Lichtenstein","year":"2021","unstructured":"Lichtenstein DA, Schischlik F, Shao L, Steinberg SM, Yates B, Wang HW, et al. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Blood. 2021;138:2469\u201384. https:\/\/doi.org\/10.1182\/blood.2021011898.","journal-title":"Blood"},{"key":"1481_CR30","doi-asserted-by":"publisher","first-page":"e358","DOI":"10.1016\/s2352-3026(24)00064-4","volume":"11","author":"NS Grover","year":"2024","unstructured":"Grover NS, Hucks G, Riches ML, Ivanova A, Moore DT, Shea TC, et al. Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30+ lymphoma: a phase 1 study. Lancet Haematol. 2024;11:e358\u201367. https:\/\/doi.org\/10.1016\/s2352-3026(24)00064-4.","journal-title":"Lancet Haematol"},{"key":"1481_CR31","doi-asserted-by":"publisher","first-page":"e384","DOI":"10.1038\/bcj.2015.112","volume":"6","author":"A Rosenthal","year":"2016","unstructured":"Rosenthal A, Luthi J, Belohlavek M, Kort\u00fcm KM, Mookadam F, Mayo A, et al. Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? Blood Cancer J. 2016;6:e384. https:\/\/doi.org\/10.1038\/bcj.2015.112.","journal-title":"Blood Cancer J"},{"key":"1481_CR32","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/hon.2535","volume":"36","author":"A Mangla","year":"2018","unstructured":"Mangla A, Paydary K, Liu J, Mbachi C, Yim B, Lad TE. Carfilzomib-associated cardiovascular adverse events in a non-Caucasian cohort of patients with multiple myeloma: a real-world experience. Hematol Oncol. 2018;36:715\u20137. https:\/\/doi.org\/10.1002\/hon.2535.","journal-title":"Hematol Oncol"},{"key":"1481_CR33","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3390\/antiox13060671","volume":"13","author":"MY George","year":"2024","unstructured":"George MY, Dabour MS, Rashad E, Zordoky BN. Empagliflozin alleviates carfilzomib-induced cardiotoxicity in mice by modulating oxidative stress, inflammatory response, endoplasmic reticulum stress, and autophagy. Antioxidants. 2024;13:671. https:\/\/doi.org\/10.3390\/antiox13060671.","journal-title":"Antioxidants"},{"key":"1481_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00849-z","volume":"13","author":"J El-Cheikh","year":"2023","unstructured":"El-Cheikh J, Moukalled N, Malard F, Bazarbachi A, Mohty M. Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies. Blood Cancer J. 2023;13:83. https:\/\/doi.org\/10.1038\/s41408-023-00849-z.","journal-title":"Blood Cancer J"},{"key":"1481_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jeaa356.424","volume":"22","author":"A Astarita","year":"2021","unstructured":"Astarita A, Mingrone G, Airale L, Vallelonga F, Catarinella C, Cesareo M, et al. Cardiovascular risk assessment in multiple myeloma patients undergoing carfilzomib therapy: a new risk prediction model for cardiovascular adverse events. Eur Heart J Cardiovasc Imaging. 2021;22:jeaa356.424. https:\/\/doi.org\/10.1093\/ehjci\/jeaa356.424.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"1481_CR36","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1182\/blood.V128.22.3319.3319","volume":"128","author":"A Chari","year":"2016","unstructured":"Chari A, Aggarwal SK, Mezzi K, Wang K, Kim C, Zhu S, et al. Cardiac events in real-world multiple myeloma patients treated with carfilzomib: a retrospective claims database analysis. Blood. 2016;128:3319. https:\/\/doi.org\/10.1182\/blood.V128.22.3319.3319.","journal-title":"Blood"},{"key":"1481_CR37","doi-asserted-by":"publisher","unstructured":"Korde N, Mastey D, Tavitian E, Mailankody S, Lesokhin A, Hassoun H, et al. Tailored treatment to MRD response: A phase I\/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56\u2009mg\/m2) in combination with lenalidomide and dexamethasone. Am J Hematol. 2021;96. https:\/\/doi.org\/10.1002\/ajh.26150","DOI":"10.1002\/ajh.26150"},{"key":"1481_CR38","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3390\/cancers15030955","volume":"15","author":"A Astarita","year":"2023","unstructured":"Astarita A, Mingrone G, Airale L, Cesareo M, Colomba A, Catarinella C, et al. Carfilzomib-based regimen and cardiotoxicity in multiple myeloma: incidence of cardiovascular events and organ damage in carfilzomib-dexamethasone versus carfilzomib-lenalidomide-dexamethasone. A real-life prospective study. Cancers. 2023;15:955. https:\/\/doi.org\/10.3390\/cancers15030955.","journal-title":"Cancers"},{"key":"1481_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1001\/jamacardio.2023.4105","volume":"9","author":"JW Rhee","year":"2024","unstructured":"Rhee JW, Pillai R, He T, Bosworth A, Chen S, Atencio L, et al. Clonal hematopoiesis and cardiovascular disease in patients with multiple myeloma undergoing hematopoietic cell transplant. JAMA Cardiol. 2024;9:16\u201324. https:\/\/doi.org\/10.1001\/jamacardio.2023.4105.","journal-title":"JAMA Cardiol"},{"key":"1481_CR40","doi-asserted-by":"publisher","first-page":"10956","DOI":"10.3390\/ijms222010956","volume":"22","author":"P Efentakis","year":"2021","unstructured":"Efentakis P, Psarakou G, Varela A, Papanagnou ED, Chatzistefanou M, Nikolaou PE, et al. Elucidating carfilzomib\u2019s induced cardiotoxicity in an in vivo model of aging: prophylactic potential of metformin. Int J Mol Sci. 2021;22:10956. https:\/\/doi.org\/10.3390\/ijms222010956.","journal-title":"Int J Mol Sci"},{"key":"1481_CR41","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1182\/blood-2018-06-858415","volume":"133","author":"P Efentakis","year":"2019","unstructured":"Efentakis P, Kremastiotis G, Varela A, Nikolaou PE, Papanagnou ED, Davos CH, et al. Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. Blood. 2019;133:710\u201323. https:\/\/doi.org\/10.1182\/blood-2018-06-858415.","journal-title":"Blood"},{"key":"1481_CR42","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1182\/blood-2020-136888","volume":"136","author":"P Efentakis","year":"2020","unstructured":"Efentakis P, Psarrakou G, Nikolaou PE, Chatzistefanou M, Papanagnou ED, Kastritis E, et al. Carfilzomib-induced cardiotoxicity in an in vivo model of aging. Blood. 2020;136:18. https:\/\/doi.org\/10.1182\/blood-2020-136888.","journal-title":"Blood"},{"key":"1481_CR43","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/ehaa946.3400","volume":"41","author":"G Psarrakou","year":"2020","unstructured":"Psarrakou G, Chatzistefanou M, Efentakis P, Varela A, Papanagnou ED, Nikolaou PE, et al. Investigating the impact of aging and hyperlipidaemia on metformin cardioprotection against carfilzomib-induced cardiotoxicity in vivo. Eur Heart J. 2020;41:ehaa946.3400. https:\/\/doi.org\/10.1093\/ehjci\/ehaa946.3400.","journal-title":"Eur Heart J"},{"key":"1481_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.121022","volume":"607","author":"X Lai","year":"2021","unstructured":"Lai X, Wang S, Hu M, Sun Y, Chen M, Liu M, et al. Dual targeting single arrow: Neutrophil-targeted sialic acid-modified nanoplatform for treating comorbid tumors and rheumatoid arthritis. Int J Pharm. 2021;607:121022. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.121022.","journal-title":"Int J Pharm"},{"key":"1481_CR45","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1161\/CIRCULATIONAHA.122.061736","volume":"148","author":"YC Cheng","year":"2023","unstructured":"Cheng YC, Hsieh ML, Lin CJ, Chang CMC, Huang CY, Puntney R, et al. Combined treatment of human induced pluripotent stem cell\u2013derived cardiomyocytes and endothelial cells regenerate the infarcted heart in mice and non-human primates. Circulation. 2023;148:1395\u2013409. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061736.","journal-title":"Circulation"},{"key":"1481_CR46","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022247","volume":"10","author":"P Forghani","year":"2021","unstructured":"Forghani P, Rashid A, Sun F, Liu R, Li D, Lee MR, et al. Carfilzomib treatment causes molecular and functional alterations of human induced pluripotent stem cell\u2013derived cardiomyocytes. J Am Heart Assoc. 2021;10:e022247. https:\/\/doi.org\/10.1161\/JAHA.121.022247.","journal-title":"J Am Heart Assoc"},{"key":"1481_CR47","doi-asserted-by":"publisher","unstructured":"Forghani P, Rashid A, Li D, Mandawat A, Xu C Abstract 499: modeling carfilzomib induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Circ Res. 2020;127. https:\/\/doi.org\/10.1161\/res.127.suppl_1.499","DOI":"10.1161\/res.127.suppl_1.499"},{"key":"1481_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46600-5","volume":"15","author":"J Currie","year":"2024","unstructured":"Currie J, Manda V, Robinson SK, Lai C, Agnihotri V, Hidalgo V, et al. Simultaneous proteome localization and turnover analysis reveals spatiotemporal features of protein homeostasis disruptions. Nat Commun. 2024;15:2207. https:\/\/doi.org\/10.1038\/s41467-024-46600-5.","journal-title":"Nat Commun"},{"key":"1481_CR49","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94623","volume":"2","author":"LM Judge","year":"2017","unstructured":"Judge LM, Perez-Bermejo JA, Truong A, Ribeiro AJS, Yoo JC, Jensen CL, et al. A BAG3 chaperone complex maintains cardiomyocyte function during proteotoxic stress. JCI Insight. 2017;2:e94623. https:\/\/doi.org\/10.1172\/jci.insight.94623.","journal-title":"JCI Insight"},{"key":"1481_CR50","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.stem.2020.05.004","volume":"26","author":"E Giacomelli","year":"2020","unstructured":"Giacomelli E, Meraviglia V, Campostrini G, Cochrane A, Cao X, Van Helden RWJ, et al. Human-iPSC-derived cardiac stromal cells enhance maturation in 3D cardiac microtissues and reveal non-cardiomyocyte contributions to heart disease. Cell Stem Cell. 2020;26:862\u201379.e11. https:\/\/doi.org\/10.1016\/j.stem.2020.05.004.","journal-title":"Cell Stem Cell"},{"key":"1481_CR51","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/cvr\/cvn128","volume":"79","author":"HY Fu","year":"2008","unstructured":"Fu HY, Minamino T, Tsukamoto O, Sawada T, Asai M, Kato H, et al. Overexpression of endoplasmic reticulum-resident chaperone attenuates cardiomyocyte death induced by proteasome inhibition. Cardiovasc Res. 2008;79:600\u201310. https:\/\/doi.org\/10.1093\/cvr\/cvn128.","journal-title":"Cardiovasc Res"},{"key":"1481_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-87442-5","volume":"15","author":"C Kelly","year":"2025","unstructured":"Kelly C, Kiltschewskij DJ, Leong AJW, Haw TJ, Croft AJ, Balachandran L, et al. Identifying common pathways for doxorubicin and carfilzomib-induced cardiotoxicities: transcriptomic and epigenetic profiling. Sci Rep. 2025;15:4395. https:\/\/doi.org\/10.1038\/s41598-025-87442-5.","journal-title":"Sci Rep"},{"key":"1481_CR53","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s11886-023-01945-z","volume":"25","author":"A Kurnick","year":"2023","unstructured":"Kurnick A, Akivis Y, Sabu J, John S. Echocardiographic evaluation of cardiac masses. Curr Cardiol Rep. 2023;25:1281\u201390. https:\/\/doi.org\/10.1007\/s11886-023-01945-z.","journal-title":"Curr Cardiol Rep"},{"key":"1481_CR54","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1002\/1878-0261.13447","volume":"17","author":"G Luo","year":"2023","unstructured":"Luo G, Aldridge K, Chen T, Aslot V, Kim B, Han EH, et al. The synthetic oleanane triterpenoid CDDO-2P-Im binds GRP78 \/ BiP to induce unfolded protein response-mediated apoptosis in myeloma. Mol Oncol. 2023;17:2526\u201345. https:\/\/doi.org\/10.1002\/1878-0261.13447.","journal-title":"Mol Oncol"},{"key":"1481_CR55","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cellsig.2015.10.013","volume":"28","author":"E Borkham-Kamphorst","year":"2016","unstructured":"Borkham-Kamphorst E, Steffen BT, Van De Leur E, Haas U, Tihaa L, Friedman SL, et al. CCN1\/CYR61 overexpression in hepatic stellate cells induces ER stress-related apoptosis. Cell Signal. 2016;28:34\u201342. https:\/\/doi.org\/10.1016\/j.cellsig.2015.10.013.","journal-title":"Cell Signal"},{"key":"1481_CR56","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jare.2021.12.009","volume":"41","author":"S Tai","year":"2022","unstructured":"Tai S, Sun J, Zhou Y, Zhu Z, He Y, Chen M, et al. Metformin suppresses vascular smooth muscle cell senescence by promoting autophagic flux. J Adv Res. 2022;41:205\u201318. https:\/\/doi.org\/10.1016\/j.jare.2021.12.009.","journal-title":"J Adv Res"},{"key":"1481_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-47774-6","volume":"13","author":"K Phadwal","year":"2023","unstructured":"Phadwal K, Tan X, Koo E, Zhu D, MacRae VE. Metformin ameliorates valve interstitial cell calcification by promoting autophagic flux. Sci Rep. 2023;13:21435. https:\/\/doi.org\/10.1038\/s41598-023-47774-6.","journal-title":"Sci Rep"},{"key":"1481_CR58","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1080\/1061186X.2020.1868478","volume":"29","author":"S Wu","year":"2021","unstructured":"Wu S, Zhang H, Chen N, Zhang C, Guo X. Metformin protects cardiomyocytes against oxygen-glucose deprivation injury by promoting autophagic flux through AMPK pathway. J Drug Target. 2021;29:551\u201361. https:\/\/doi.org\/10.1080\/1061186X.2020.1868478.","journal-title":"J Drug Target"},{"key":"1481_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.621509","volume":"8","author":"T Li","year":"2021","unstructured":"Li T, Yin Y, Mu N, Wang Y, Liu M, Chen M, et al. Metformin-enhanced cardiac AMP-activated protein kinase\/atrogin-1 pathways inhibit charged multivesicular body protein 2B accumulation in ischemia\u2013reperfusion injury. Front Cell Dev Biol. 2021;8:621509. https:\/\/doi.org\/10.3389\/fcell.2020.621509.","journal-title":"Front Cell Dev Biol"},{"key":"1481_CR60","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.3390\/ijms22073701","volume":"22","author":"SCH Rehfeldt","year":"2021","unstructured":"Rehfeldt SCH, Laufer S, Goettert MI. A highly selective in vitro JNK3 inhibitor, FMU200, restores mitochondrial membrane potential and reduces oxidative stress and apoptosis in SH-SY5Y cells. Int J Mol Sci. 2021;22:3701. https:\/\/doi.org\/10.3390\/ijms22073701.","journal-title":"Int J Mol Sci"},{"key":"1481_CR61","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.freeradbiomed.2023.06.019","volume":"206","author":"T Ye","year":"2023","unstructured":"Ye T, Yang W, Gao T, Yu X, Chen T, Yang Y, et al. Trastuzumab-induced cardiomyopathy via ferroptosis-mediated mitochondrial dysfunction. Free Radic Biol Med. 2023;206:143\u201361. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2023.06.019.","journal-title":"Free Radic Biol Med"},{"key":"1481_CR62","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/sj.bjp.0705384","volume":"139","author":"DV Folden","year":"2003","unstructured":"Folden DV, Gupta A, Sharma AC, Li S, Saari JT, Ren J. Malondialdehyde inhibits cardiac contractile function in ventricular myocytes via a p38 mitogen-activated protein kinase-dependent mechanism. Br J Pharmacol. 2003;139:1310\u20136. https:\/\/doi.org\/10.1038\/sj.bjp.0705384.","journal-title":"Br J Pharmacol"},{"key":"1481_CR63","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/toxres\/tfad007","volume":"12","author":"M Chen","year":"2023","unstructured":"Chen M. Empagliflozin attenuates doxorubicin-induced cardiotoxicity by activating AMPK\/SIRT-1\/PGC-1\u03b1-mediated mitochondrial biogenesis. Toxicol Res. 2023;12:216\u201323. https:\/\/doi.org\/10.1093\/toxres\/tfad007.","journal-title":"Toxicol Res"},{"key":"1481_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.121207","volume":"312","author":"J Min","year":"2023","unstructured":"Min J, Wu L, Liu Y, Song G, Deng Q, Jin W, et al. Empagliflozin attenuates trastuzumab-induced cardiotoxicity through suppression of DNA damage and ferroptosis. Life Sci. 2023;312:121207. https:\/\/doi.org\/10.1016\/j.lfs.2022.121207.","journal-title":"Life Sci"},{"key":"1481_CR65","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.4161\/auto.22185","volume":"8","author":"Y Zang","year":"2012","unstructured":"Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, et al. The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4. Autophagy. 2012;8:1873\u20134. https:\/\/doi.org\/10.4161\/auto.22185.","journal-title":"Autophagy"},{"key":"1481_CR66","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1080\/15548627.2020.1802089","volume":"17","author":"X Wu","year":"2021","unstructured":"Wu X, Zheng Y, Liu M, Li Y, Ma S, Tang W, et al. BNIP3L\/NIX degradation leads to mitophagy deficiency in ischemic brains. Autophagy. 2021;17:1934\u201346. https:\/\/doi.org\/10.1080\/15548627.2020.1802089.","journal-title":"Autophagy"},{"key":"1481_CR67","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s12265-019-09873-6","volume":"12","author":"W Zhou","year":"2019","unstructured":"Zhou W, Bos JM, Ye D, Tester DJ, Hrstka S, Maleszewski JJ, et al. Induced pluripotent stem cell\u2013derived cardiomyocytes from a patient with MYL2-R58Q-mediated apical hypertrophic cardiomyopathy show hypertrophy, myofibrillar disarray, and calcium perturbations. J Cardiovasc Transl Res. 2019;12:394\u2013403. https:\/\/doi.org\/10.1007\/s12265-019-09873-6.","journal-title":"J Cardiovasc Transl Res"},{"key":"1481_CR68","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.128799","volume":"4","author":"C McDermott-Roe","year":"2019","unstructured":"McDermott-Roe C, Lv W, Maximova T, Wada S, Bukowy J, Marquez M, et al. Investigation of a dilated cardiomyopathy\u2013associated variant in BAG3 using genome-edited iPSC-derived cardiomyocytes. JCI Insight. 2019;4:e128799. https:\/\/doi.org\/10.1172\/jci.insight.128799.","journal-title":"JCI Insight"},{"key":"1481_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2019.106271","volume":"88","author":"MR Pierce","year":"2020","unstructured":"Pierce MR, Robinson RM, Ibarra-Rivera TR, Pirrung MC, Dolloff NG, Bachmann AS. Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo. Leuk Res. 2020;88:106271. https:\/\/doi.org\/10.1016\/j.leukres.2019.106271.","journal-title":"Leuk Res"},{"key":"1481_CR70","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1182\/blood-2020-139277","volume":"136","author":"MA Mendez","year":"2020","unstructured":"Mendez MA, Besse A, Florea BI, Zuppinger C, Overkleeft HS, Besse L, et al. All-trans-retinoic acid prevents carfilzomib-induced cardiotoxicity by decreasing activation of the renin-angiotensin system. Blood. 2020;136:19\u201320. https:\/\/doi.org\/10.1182\/blood-2020-139277.","journal-title":"Blood"},{"key":"1481_CR71","doi-asserted-by":"crossref","unstructured":"Engelhardt M, Szymaniak-Vits M, Ajayi S, Dold SM, M\u00fcller SJ, Scheubeck S, et al. Carfilzomib. In: Martens UM, editor. Small molecules in hematology. Cham: Springer International Publishing; 2018. http:\/\/link.springer.com\/10.1007\/978-3-319-91439-8_13.","DOI":"10.1007\/978-3-319-91439-8_13"},{"key":"1481_CR72","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ejphar.2018.09.014","volume":"838","author":"M Gavazzoni","year":"2018","unstructured":"Gavazzoni M, Lombardi CM, Vizzardi E, Gorga E, Sciatti E, Rossi L, et al. Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: Early in vivo cardiovascular effects. Eur J Pharmacol. 2018;838:85\u201390. https:\/\/doi.org\/10.1016\/j.ejphar.2018.09.014.","journal-title":"Eur J Pharmacol"},{"key":"1481_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2022.155250","volume":"134","author":"SR Brand\u00e3o","year":"2022","unstructured":"Brand\u00e3o SR, Carvalho F, Amado F, Ferreira R, Costa VM. Insights on the molecular targets of cardiotoxicity induced by anticancer drugs: a systematic review based on proteomic findings. Metabolism. 2022;134:155250. https:\/\/doi.org\/10.1016\/j.metabol.2022.155250.","journal-title":"Metabolism"},{"key":"1481_CR74","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.tox.2016.04.010","volume":"353\u20134","author":"EM Spur","year":"2016","unstructured":"Spur EM, Althof N, Respondek D, Klingel K, Heuser A, Overkleeft HS, et al. Inhibition of chymotryptic-like standard proteasome activity exacerbates doxorubicin-induced cytotoxicity in primary cardiomyocytes. Toxicology. 2016;353\u20134:34\u201347. https:\/\/doi.org\/10.1016\/j.tox.2016.04.010.","journal-title":"Toxicology"},{"key":"1481_CR75","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.yjmcc.2018.05.102","volume":"120","author":"G Kremastiotis","year":"2018","unstructured":"Kremastiotis G, Efentakis P, Varela A, Davos CH, Tsoumani M, Papanagnou ED, et al. The proteasome inhibitor carfilzomib (Cfz) induces cardiotoxicity in vivo: molecular mechanisms and the cardioprotective effect of metformin (Met). J Mol Cell Cardiol. 2018;120:33. https:\/\/doi.org\/10.1016\/j.yjmcc.2018.05.102.","journal-title":"J Mol Cell Cardiol"},{"key":"1481_CR76","doi-asserted-by":"publisher","first-page":"46","DOI":"10.4161\/15548627.2014.984271","volume":"11","author":"YM Song","year":"2015","unstructured":"Song YM, Lee Yho, Kim JW, Ham DS, Kang ES, Cha BS, et al. Metformin alleviates hepatosteatosis by restoring SIRT1-mediated autophagy induction via an AMP-activated protein kinase-independent pathway. Autophagy. 2015;11:46\u201359. https:\/\/doi.org\/10.4161\/15548627.2014.984271.","journal-title":"Autophagy"},{"key":"1481_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102288","volume":"52","author":"C Cai","year":"2022","unstructured":"Cai C, Guo Z, Chang X, Li Z, Wu F, He J, et al. Empagliflozin attenuates cardiac microvascular ischemia\/reperfusion through activating the AMPK\u03b11\/ULK1\/FUNDC1\/mitophagy pathway. Redox Biol. 2022;52:102288. https:\/\/doi.org\/10.1016\/j.redox.2022.102288.","journal-title":"Redox Biol"},{"key":"1481_CR78","doi-asserted-by":"publisher","unstructured":"Schauer A, Adams V, K\u00e4mmerer S, Langner E, Augstein A, Barthel P, et al. Empagliflozin improves diastolic function in HFpEF by restabilizing the mitochondrial respiratory chain. Circ Heart Fail. 2024;17. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.123.011107","DOI":"10.1161\/CIRCHEARTFAILURE.123.011107"},{"key":"1481_CR79","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/cvr\/cvaa123","volume":"117","author":"D Kolijn","year":"2021","unstructured":"Kolijn D, Pabel S, Tian Y, L\u00f3di M, Herwig M, Carrizzo A, et al. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase G\u03b1 oxidation. Cardiovasc Res. 2021;117:495\u2013507. https:\/\/doi.org\/10.1093\/cvr\/cvaa123.","journal-title":"Cardiovasc Res"},{"key":"1481_CR80","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1182\/blood.2020009856","volume":"139","author":"Q Wang","year":"2022","unstructured":"Wang Q, Lin Z, Wang Z, Ye L, Xian M, Xiao L, et al. RAR\u03b3 activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway. Blood. 2022;139:59\u201372. https:\/\/doi.org\/10.1182\/blood.2020009856.","journal-title":"Blood"},{"key":"1481_CR81","doi-asserted-by":"publisher","unstructured":"Erratum to: 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J. 2023;44:1621. https:\/\/doi.org\/10.1093\/eurheartj\/ehad196.","DOI":"10.1093\/eurheartj\/ehad196"},{"key":"1481_CR82","doi-asserted-by":"publisher","first-page":"10842","DOI":"10.3390\/ijms241310842","volume":"24","author":"T Matsumoto","year":"2023","unstructured":"Matsumoto T, Matsumoto J, Matsushita Y, Arimura M, Aono K, Aoki M, et al. Bortezomib increased vascular permeability by decreasing cell\u2013cell junction molecules in human pulmonary microvascular endothelial cells. Int J Mol Sci. 2023;24:10842. https:\/\/doi.org\/10.3390\/ijms241310842.","journal-title":"Int J Mol Sci"},{"key":"1481_CR83","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.yexcr.2009.11.005","volume":"316","author":"D Belloni","year":"2010","unstructured":"Belloni D, Veschini L, Foglieni C, Dell\u2019Antonio G, Caligaris-Cappio F, Ferrarini M, et al. Bortezomib induces autophagic death in proliferating human endothelial cells. Exp Cell Res. 2010;316:1010\u20138. https:\/\/doi.org\/10.1016\/j.yexcr.2009.11.005.","journal-title":"Exp Cell Res"},{"key":"1481_CR84","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1165\/rcmb.2011-0331OC","volume":"47","author":"SY Kim","year":"2012","unstructured":"Kim SY, Lee JH, Huh JW, Kim HJ, Park MK, Ro JY, et al. Bortezomib alleviates experimental pulmonary arterial hypertension. Am J Respir Cell Mol Biol. 2012;47:698\u2013708. https:\/\/doi.org\/10.1165\/rcmb.2011-0331OC.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"1481_CR85","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13828","volume":"17","author":"S Shabnaz","year":"2024","unstructured":"Shabnaz S, Nguyen TN, Williams R, Rubinstein SM, Garrett TJ, Tantawy M, et al. Metabolomic signatures of carfilzomib-related cardiotoxicity in patients with multiple myeloma. Clin Transl Sci. 2024;17:e13828. https:\/\/doi.org\/10.1111\/cts.13828.","journal-title":"Clin Transl Sci"},{"key":"1481_CR86","doi-asserted-by":"publisher","unstructured":"Currie J, Manda V, Hidalgo V, Ludwig RW, Lam MP, Lau E. Abstract P1184: spatiotemporal proteomics approach to discern new features of carfilzomib-mediated cardiotoxicity. Circ Res. 2023;133. https:\/\/doi.org\/10.1161\/res.133.suppl_1.P1184","DOI":"10.1161\/res.133.suppl_1.P1184"},{"key":"1481_CR87","doi-asserted-by":"publisher","first-page":"3872","DOI":"10.7150\/thno.80801","volume":"13","author":"Y Gao","year":"2023","unstructured":"Gao Y, Su L, Wei Y, Tan S, Hu Z, Tao Z, et al. Ascorbic acid induces MLC2v protein expression and promotes ventricular-like cardiomyocyte subtype in human induced pluripotent stem cells derived cardiomyocytes. Theranostics. 2023;13:3872\u201396. https:\/\/doi.org\/10.7150\/thno.80801.","journal-title":"Theranostics"},{"key":"1481_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04467-y","volume":"21","author":"H Liu","year":"2023","unstructured":"Liu H, Wang L, Xu H, Tan B, Yi Q, Deng H, et al. Quantitative proteomic and phosphoproteomic analysis reveal the relationship between mitochondrial dysfunction and cytoskeletal remodeling in hiPSC-CMs deficient in PINK1. J Transl Med. 2023;21:581. https:\/\/doi.org\/10.1186\/s12967-023-04467-y.","journal-title":"J Transl Med"},{"key":"1481_CR89","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1182\/blood-2018-99-113792","volume":"132","author":"E Kastritis","year":"2018","unstructured":"Kastritis E, Laina A, Gavriatopoulou M, Georgiopoulos G, Eleutherakis-Papaiakovou E, Despina F, et al. Carfilzomib induces acute endothelial dysfunction which correlates with the occurrence of cardiovascular events. Blood. 2018;132:3247. https:\/\/doi.org\/10.1182\/blood-2018-99-113792.","journal-title":"Blood"},{"key":"1481_CR90","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/s41375-021-01141-4","volume":"35","author":"E Kastritis","year":"2021","unstructured":"Kastritis E, Laina A, Georgiopoulos G, Gavriatopoulou M, Papanagnou ED, Eleutherakis-Papaiakovou E, et al. Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study. Leukemia. 2021;35:1418\u201327. https:\/\/doi.org\/10.1038\/s41375-021-01141-4.","journal-title":"Leukemia"},{"key":"1481_CR91","doi-asserted-by":"publisher","first-page":"5185","DOI":"10.3390\/ijms21155185","volume":"21","author":"P Efentakis","year":"2020","unstructured":"Efentakis P, Doerschmann H, Witzler C, Siemer S, Nikolaou PE, Kastritis E, et al. Investigating the vascular toxicity outcomes of the irreversible proteasome inhibitor carfilzomib. Int J Mol Sci. 2020;21:5185. https:\/\/doi.org\/10.3390\/ijms21155185.","journal-title":"Int J Mol Sci"},{"key":"1481_CR92","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1182\/blood-2019-123522","volume":"134","author":"P Efentakis","year":"2019","unstructured":"Efentakis P, Andreadou I, Nikolaou PE, Witzler C, Siemer S, Kastritis E, et al. Synergistic effect of carfilzomib and metformin in vascular plasticity; the emerging role of autophagy. Blood. 2019;134:3797. https:\/\/doi.org\/10.1182\/blood-2019-123522.","journal-title":"Blood"},{"key":"1481_CR93","doi-asserted-by":"publisher","unstructured":"Mansson Broberg AGNETA, Wardell EVA, Sjoborg Alpman M, Lund JL, Sylven C. Endothelial cellular response to oxidative stress key to proteasome inhibitor cardiovascular toxicity profile. Cardiovasc Res. 2024;120:cvae088.210 https:\/\/doi.org\/10.1093\/cvr\/cvae088.210","DOI":"10.1093\/cvr\/cvae088.210"},{"key":"1481_CR94","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.canlet.2021.02.020","volume":"507","author":"MK Prelowska","year":"2021","unstructured":"Prelowska MK, Mehlich D, Ugurlu MT, Kedzierska H, Cwiek A, Kosnik A, et al. Inhibition of the \u029f-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors. Cancer Lett. 2021;507:13\u201325. https:\/\/doi.org\/10.1016\/j.canlet.2021.02.020.","journal-title":"Cancer Lett"},{"key":"1481_CR95","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1158\/1078-0432.CCR-12-2754","volume":"19","author":"SV Gupta","year":"2013","unstructured":"Gupta SV, Hertlein E, Lu Y, Sass EJ, Lapalombella R, Chen TL, et al. The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-\u03baB response in chronic lymphocytic leukemia cells. Clin Cancer Res. 2013;19:2406\u201319. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2754.","journal-title":"Clin Cancer Res"},{"key":"1481_CR96","doi-asserted-by":"publisher","unstructured":"Jannuzzi AT, Korkmaz NS, Gunaydin Akyildiz A, Arslan Eseryel S, Karademir Yilmaz B, Alpertunga B. Molecular cardiotoxic effects of proteasome inhibitors carfilzomib and ixazomib and their combination with dexamethasone involve mitochondrial dysregulation. Cardiovasc Toxicol. 2023. https:\/\/doi.org\/10.1007\/s12012-023-09785-7","DOI":"10.1007\/s12012-023-09785-7"},{"key":"1481_CR97","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.exphem.2022.04.003","volume":"111","author":"D Daniely","year":"2022","unstructured":"Daniely D, Forouzan E, Spektor TM, Cohen A, Bitran JD, Chen G, et al. A phase 1\/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimen. Exp Hematol. 2022;111:79\u201386. https:\/\/doi.org\/10.1016\/j.exphem.2022.04.003.","journal-title":"Exp Hematol"},{"key":"1481_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107579","volume":"213","author":"GR Tundo","year":"2020","unstructured":"Tundo GR, Sbardella D, Santoro AM, Coletta A, Oddone F, Grasso G, et al. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges. Pharmacol Ther. 2020;213:107579. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107579.","journal-title":"Pharmacol Ther"},{"key":"1481_CR99","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.3324\/haematol.2021.278399","volume":"106","author":"KL Yong","year":"2021","unstructured":"Yong KL, Hinsley S, Auner HW, Bygrave C, Kaiser MF, Ramasamy K, et al. Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive). Haematologica. 2021;106:2694\u2013706. https:\/\/doi.org\/10.3324\/haematol.2021.278399.","journal-title":"Haematologica"},{"key":"1481_CR100","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/ajh.24608","volume":"92","author":"H Jouni","year":"2017","unstructured":"Jouni H, Aubry MC, Lacy MQ, Vincent Rajkumar S, Kumar SK, Frye RL, et al. Ixazomib cardiotoxicity: a possible class effect of proteasome inhibitors. Am J Hematol. 2017;92:220\u20131. https:\/\/doi.org\/10.1002\/ajh.24608.","journal-title":"Am J Hematol"},{"key":"1481_CR101","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.70038","volume":"6","author":"BJ Lee","year":"2025","unstructured":"Lee BJ, Sayer M, Naqvi AA, Mai KT, Patel PM, Lee LX, et al. Balancing the risk of cardiotoxicity outcomes in treatment selection for multiple myeloma: a retrospective multicenter evaluation of ixazomib, lenalidomide, and dexamethasone (IRd) versus carfilzomib, lenalidomide, and dexamethasone (KRd). eJHaem. 2025;6:e70038. https:\/\/doi.org\/10.1002\/jha2.70038.","journal-title":"eJHaem"},{"key":"1481_CR102","doi-asserted-by":"publisher","first-page":"AMo004","DOI":"10.1161\/res.135.suppl_1.Mo004","volume":"135","author":"MY George","year":"2024","unstructured":"George MY, Dabour M, Rashad E, Zordoky B. Abstract Mo004: the protective effects of empagliflozin in carfilzomib-induced cardiotoxicity in mice: unveiling the crosstalk between oxidative stress, inflammation, endoplasmic reticulum stress, and autophagy axes. Circ Res. 2024;135:AMo004. https:\/\/doi.org\/10.1161\/res.135.suppl_1.Mo004.","journal-title":"Circ Res"},{"key":"1481_CR103","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11845-009-0282-z","volume":"179","author":"MC Barry","year":"2010","unstructured":"Barry MC, Hendriks JM, Van Dijk LC, Pattynama P, Poldermans D, Bouchier Hayes D, et al. A comparative study of myocardial injury during conventional and endovascular aortic aneurysm repair: measurement of cardiac troponin T and plasma cytokine release. Ir J Med Sci. 2010;179:35\u201342. https:\/\/doi.org\/10.1007\/s11845-009-0282-z.","journal-title":"Ir J Med Sci"},{"key":"1481_CR104","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","volume":"5","author":"M Pennisi","year":"2021","unstructured":"Pennisi M, Sanchez-Escamilla M, Flynn JR, Shouval R, Alarcon Tomas A, Silverberg ML, et al. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Adv. 2021;5:3397\u2013406. https:\/\/doi.org\/10.1182\/bloodadvances.2020003885.","journal-title":"Blood Adv"},{"key":"1481_CR105","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398:314\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(21)00933-8.","journal-title":"Lancet"},{"key":"1481_CR106","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41:1265\u201374. https:\/\/doi.org\/10.1200\/JCO.22.00842.","journal-title":"J Clin Oncol"},{"key":"1481_CR107","doi-asserted-by":"publisher","unstructured":"Golec S, Pileggi B, Moshier E, Peleg A, Rossi A, Sahni G. Abstract 12461: early use of tocilizumab following cytokine release syndrome during CAR-T therapy for multiple myeloma may be associated with fewer short and long term adverse cardiovascular events. Circulation. 2023;148. https:\/\/doi.org\/10.1161\/circ.148.suppl_1.12461","DOI":"10.1161\/circ.148.suppl_1.12461"},{"key":"1481_CR108","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","volume":"397","author":"O Abani","year":"2021","unstructured":"Abani O, Abbas A, Abbas F, Abbas M, Abbasi S, Abbass H, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637\u201345. https:\/\/doi.org\/10.1016\/S0140-6736(21)00676-0.","journal-title":"Lancet"},{"key":"1481_CR109","doi-asserted-by":"publisher","unstructured":"Lee ZC, Noviani M, Yap J, Chin CWL, Ng SA, Low AHL. Tocilizumab for systemic sclerosis with cardiac involvement: a case report. Clin Exp Rheumatol. 2022. https:\/\/doi.org\/10.55563\/clinexprheumatol\/cibdmf.","DOI":"10.55563\/clinexprheumatol\/cibdmf"},{"key":"1481_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00963-y","volume":"13","author":"SA Scott","year":"2023","unstructured":"Scott SA, Marin EM, Maples KT, Joseph NS, Hofmeister CC, Gupta VA, et al. Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: a single-center experience. Blood Cancer J. 2023;13:191. https:\/\/doi.org\/10.1038\/s41408-023-00963-y.","journal-title":"Blood Cancer J"},{"key":"1481_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.623610","volume":"12","author":"Y Chen","year":"2021","unstructured":"Chen Y, Li R, Shang S, Yang X, Li L, Wang W, et al. Therapeutic potential of TNF\u03b1 and IL1\u03b2 blockade for CRS\/ICANS in CAR-T therapy via ameliorating endothelial activation. Front Immunol. 2021;12:623610. https:\/\/doi.org\/10.3389\/fimmu.2021.623610.","journal-title":"Front Immunol"},{"key":"1481_CR112","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032172","volume":"13","author":"C Livia","year":"2024","unstructured":"Livia C, Inglis S, Crespo-Diaz R, Rizzo S, Mahlberg R, Bagwell M, et al. Infliximab limits injury in myocardial infarction. J Am Heart Assoc. 2024;13:e032172. https:\/\/doi.org\/10.1161\/JAHA.123.032172.","journal-title":"J Am Heart Assoc"},{"key":"1481_CR113","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.cellimm.2004.09.003","volume":"230","author":"F Payvandi","year":"2004","unstructured":"Payvandi F, Wu L, Haley M, Schafer PH, Zhang LH, Chen RS, et al. Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-\u03b1, IL-1\u03b2, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell Immunol. 2004;230:81\u20138. https:\/\/doi.org\/10.1016\/j.cellimm.2004.09.003.","journal-title":"Cell Immunol"},{"key":"1481_CR114","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1046\/j.1365-2141.1999.01193.x","volume":"104","author":"HIA Sati","year":"1999","unstructured":"Sati HIA, Greaves M, Apperley JF, Russell RGG, Croucher PI. Expression of interleukin-1\u03b2 and tumour necrosis factor-\u03b1 in plasma cells from patients with multiple myeloma. Br J Haematol. 1999;104:350\u20137. https:\/\/doi.org\/10.1046\/j.1365-2141.1999.01193.x.","journal-title":"Br J Haematol"},{"key":"1481_CR115","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1083\/jcb.201109067","volume":"197","author":"ST Lim","year":"2012","unstructured":"Lim ST, Miller NLG, Chen XL, Tancioni I, Walsh CT, Lawson C, et al. Nuclear-localized focal adhesion kinase regulates inflammatory VCAM-1 expression. J Cell Biol. 2012;197:907\u201319. https:\/\/doi.org\/10.1083\/jcb.201109067.","journal-title":"J Cell Biol"},{"key":"1481_CR116","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/bjh.19497","volume":"205","author":"R Shouval","year":"2024","unstructured":"Shouval R, Goldman A, Flynn JR, El-Moghraby A, Rehman M, Devlin SM, et al. Atrial arrhythmias following CAR-chimeric antigen receptor T-cell therapy: Incidence, risk factors and biomarker profile. Br J Haematol. 2024;205:978\u201389. https:\/\/doi.org\/10.1111\/bjh.19497.","journal-title":"Br J Haematol"},{"key":"1481_CR117","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40959-024-00218-0","volume":"10","author":"M Camilli","year":"2024","unstructured":"Camilli M, Viscovo M, Felici T, Maggio L, Ballacci F, Carella G, et al. Inflammation and acute cardiotoxicity in adult hematological patients treated with CAR-T cells: results from a pilot proof-of-concept study. Cardio-Oncol. 2024;10:18. https:\/\/doi.org\/10.1186\/s40959-024-00218-0.","journal-title":"Cardio-Oncol"},{"key":"1481_CR118","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40959-023-00170-5","volume":"9","author":"DH Lee","year":"2023","unstructured":"Lee DH, Chandrasekhar S, Jain MD, Mhaskar R, Reid K, Lee SB, et al. Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study. Cardio-Oncol. 2023;9:18. https:\/\/doi.org\/10.1186\/s40959-023-00170-5.","journal-title":"Cardio-Oncol"},{"key":"1481_CR119","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.3324\/haematol.2021.280009","volume":"107","author":"RE Steiner","year":"2021","unstructured":"Steiner RE, Banchs J, Koutroumpakis E, Becnel M, Gutierrez C, Strati P, et al. Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma. Haematologica. 2021;107:1555\u201366. https:\/\/doi.org\/10.3324\/haematol.2021.280009.","journal-title":"Haematologica"},{"key":"1481_CR120","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-06035-4","volume":"23","author":"Y Liu","year":"2025","unstructured":"Liu Y, Yuan X, Yang X, Yang B, Liu G, Xu X, et al. Risk analysis of cardiovascular toxicity in patients with lymphoma treated with CD19 CAR T cells. J Transl Med. 2025;23:8. https:\/\/doi.org\/10.1186\/s12967-024-06035-4.","journal-title":"J Transl Med"},{"key":"1481_CR121","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40164-021-00209-2","volume":"10","author":"L Zhang","year":"2021","unstructured":"Zhang L, Wang S, Xu J, Zhang R, Zhu H, Wu Y, et al. Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy. Exp Hematol Oncol. 2021;10:16. https:\/\/doi.org\/10.1186\/s40164-021-00209-2.","journal-title":"Exp Hematol Oncol"},{"key":"1481_CR122","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"ES Chung","year":"2003","unstructured":"Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-\u03b1, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation. 2003;107:3133\u201340. https:\/\/doi.org\/10.1161\/01.CIR.0000077913.60364.D2.","journal-title":"Circulation"},{"key":"1481_CR123","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1182\/blood-2023-185236","volume":"142","author":"Y Hu","year":"2023","unstructured":"Hu Y, Li X, Jiang P, Yang T, Gu T, Si X, et al. A multi-omic single-cell landscape of cytokine release syndrome in multiple myeloma patients after anti-BCMA CAR-T cell therapy. Blood. 2023;142:101. https:\/\/doi.org\/10.1182\/blood-2023-185236.","journal-title":"Blood"},{"key":"1481_CR124","doi-asserted-by":"publisher","unstructured":"Chaidos A, Katsarou A, Mustafa C, Milojkovic D, Karadimitris A. Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma. Br J Haematol. 2020;190. https:\/\/doi.org\/10.1111\/bjh.16787","DOI":"10.1111\/bjh.16787"},{"key":"1481_CR125","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.intimp.2005.05.010","volume":"5","author":"M Mihara","year":"2005","unstructured":"Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005;5:1731\u201340. https:\/\/doi.org\/10.1016\/j.intimp.2005.05.010.","journal-title":"Int Immunopharmacol"},{"key":"1481_CR126","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1002\/stem.3093","volume":"37","author":"VYF Su","year":"2019","unstructured":"Su VYF, Chiou SH, Lin CS, Mo MH, Yang KY. Induced Pluripotent stem cells attenuate endothelial leakage in acute lung injury via tissue inhibitor of metalloproteinases-1 to reduce focal adhesion kinase activity. Stem Cells. 2019;37:1516\u201327. https:\/\/doi.org\/10.1002\/stem.3093.","journal-title":"Stem Cells"},{"key":"1481_CR127","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.3390\/jcm13061574","volume":"13","author":"S Barachini","year":"2024","unstructured":"Barachini S, Buda G, Petrini I. Cardiovascular toxicity of antineoplastic treatments in hematological diseases: focus on molecular mechanisms to improve therapeutic management. J Clin Med. 2024;13:1574. https:\/\/doi.org\/10.3390\/jcm13061574.","journal-title":"J Clin Med"},{"key":"1481_CR128","doi-asserted-by":"publisher","first-page":"6282","DOI":"10.1182\/bloodadvances.2024013849","volume":"8","author":"M Munir","year":"2024","unstructured":"Munir M, Sayed A, Addison D, Epperla N. Cardiovascular toxicities associated with novel cellular immune therapies. Blood Adv. 2024;8:6282\u201396. https:\/\/doi.org\/10.1182\/bloodadvances.2024013849.","journal-title":"Blood Adv"},{"key":"1481_CR129","doi-asserted-by":"publisher","first-page":"6330","DOI":"10.3390\/curroncol30070467","volume":"30","author":"M Markouli","year":"2023","unstructured":"Markouli M, Ullah F, Unlu S, Omar N, Lopetegui-Lia N, Duco M, et al. Toxicity profile of chimeric antigen receptor T-cell and bispecific antibody therapies in multiple myeloma: pathogenesis, prevention and management. Curr Oncol. 2023;30:6330\u201352. https:\/\/doi.org\/10.3390\/curroncol30070467.","journal-title":"Curr Oncol"},{"key":"1481_CR130","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1200\/OP.22.00713","volume":"19","author":"RI Marar","year":"2023","unstructured":"Marar RI, Abbasi MA, Prathivadhi-Bhayankaram S, Daryanani A, Villarraga H, Anavekar N, et al. Cardiotoxicities of novel therapies in hematologic malignancies: chimeric antigen receptor T-cell therapy and bispecific T-cell engager therapy. JCO Oncol Pract. 2023;19:331\u201342. https:\/\/doi.org\/10.1200\/OP.22.00713.","journal-title":"JCO Oncol Pract"},{"key":"1481_CR131","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.924208","volume":"12","author":"LR Chen","year":"2022","unstructured":"Chen LR, Li YJ, Zhang Z, Wang P, Zhou T, Qian K, et al. Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: a meta-analysis. Front Oncol. 2022;12:924208. https:\/\/doi.org\/10.3389\/fonc.2022.924208.","journal-title":"Front Oncol"},{"key":"1481_CR132","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s43856-024-00540-9","volume":"4","author":"B Karthikeyan","year":"2024","unstructured":"Karthikeyan B, Sunder SS, Puzanov I, Olejniczak SH, Pokharel S, Sharma UC. Cardiotoxic profiles of CAR-T therapy and bispecific T-cell engagers in hematological cancers. Commun Med. 2024;4:116. https:\/\/doi.org\/10.1038\/s43856-024-00540-9.","journal-title":"Commun Med"},{"key":"1481_CR133","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s00210-020-01870-w","volume":"393","author":"MS \u00c7\u00f6mez","year":"2020","unstructured":"\u00c7\u00f6mez MS, Cellat M, \u00d6zkan H, Borazan Y, Ayd\u0131n T, G\u00f6k\u00e7ek \u0130, et al. Protective effect of oleuropein on ketamine-induced cardiotoxicity in rats. Naunyn Schmiedebergs Arch Pharmacol. 2020;393:1691\u20139. https:\/\/doi.org\/10.1007\/s00210-020-01870-w.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"1481_CR134","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1161\/CIRCRESAHA.120.315894","volume":"128","author":"AH Baik","year":"2021","unstructured":"Baik AH, Oluwole OO, Johnson DB, Shah N, Salem JE, Tsai KK, et al. Mechanisms of cardiovascular toxicities associated with immunotherapies. Circ Res. 2021;128:1780\u2013801. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.315894.","journal-title":"Circ Res"},{"key":"1481_CR135","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s12012-020-09625-y","volume":"21","author":"G Durdagi","year":"2021","unstructured":"Durdagi G, Pehlivan DY, Oyar EO, Bahceci SA, Ozbek M. Effects of melatonin and adrenomedullin in reducing the cardiotoxic effects of doxorubicin in rats. Cardiovasc Toxicol. 2021;21:354\u201364. https:\/\/doi.org\/10.1007\/s12012-020-09625-y.","journal-title":"Cardiovasc Toxicol"},{"key":"1481_CR136","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.2004659","volume":"10","author":"J An","year":"2021","unstructured":"An J, Feng L, Ren J, Li Y, Li G, Liu C, et al. Chronic stress promotes breast carcinoma metastasis by accumulating myeloid-derived suppressor cells through activating \u03b2-adrenergic signaling. OncoImmunology. 2021;10:2004659. https:\/\/doi.org\/10.1080\/2162402X.2021.2004659.","journal-title":"OncoImmunology"},{"key":"1481_CR137","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.brainres.2018.04.023","volume":"1692","author":"J Matsumoto","year":"2018","unstructured":"Matsumoto J, Dohgu S, Takata F, Machida T, B\u00f6l\u00fckba\u015fi Hatip FF, Hatip-Al-Khatib I, et al. TNF-\u03b1-sensitive brain pericytes activate microglia by releasing IL-6 through cooperation between I\u03baB-NF\u03baB and JAK-STAT3 pathways. Brain Res. 2018;1692:34\u201344. https:\/\/doi.org\/10.1016\/j.brainres.2018.04.023.","journal-title":"Brain Res"},{"key":"1481_CR138","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s10753-019-00978-3","volume":"42","author":"YL Xue","year":"2019","unstructured":"Xue YL, Zhang SX, Zheng CF, Li YF, Zhang LH, Hao YF, et al. Silencing of STAT4 protects against autoimmune myocarditis by regulating Th1\/Th2 immune response via inactivation of the NF-\u03baB pathway in rats. Inflammation. 2019;42:1179\u201389. https:\/\/doi.org\/10.1007\/s10753-019-00978-3.","journal-title":"Inflammation"},{"key":"1481_CR139","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.virol.2016.08.009","volume":"498","author":"MK McCarthy","year":"2016","unstructured":"McCarthy MK, Malitz DH, Molloy CT, Procario MC, Greiner KE, Zhang L, et al. Interferon-dependent immunoproteasome activity during mouse adenovirus type 1 infection. Virology. 2016;498:57\u201368. https:\/\/doi.org\/10.1016\/j.virol.2016.08.009.","journal-title":"Virology"},{"key":"1481_CR140","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.755862","volume":"12","author":"JPS Nunes","year":"2021","unstructured":"Nunes JPS, Andrieux P, Brochet P, Almeida RR, Kitano E, Honda AK, et al. Co-exposure of cardiomyocytes to IFN-\u03b3 and TNF-\u03b1 induces mitochondrial dysfunction and nitro-oxidative stress: implications for the pathogenesis of chronic chagas disease cardiomyopathy. Front Immunol. 2021;12:755862. https:\/\/doi.org\/10.3389\/fimmu.2021.755862.","journal-title":"Front Immunol"},{"key":"1481_CR141","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.708325","volume":"11","author":"KA Hoffman","year":"2021","unstructured":"Hoffman KA, Villar MJ, Poveda C, Bottazzi ME, Hotez PJ, Tweardy DJ, et al. Signal transducer and activator of transcription-3 modulation of cardiac pathology in chronic chagasic cardiomyopathy. Front Cell Infect Microbiol. 2021;11:708325. https:\/\/doi.org\/10.3389\/fcimb.2021.708325.","journal-title":"Front Cell Infect Microbiol"},{"key":"1481_CR142","doi-asserted-by":"publisher","first-page":"6260","DOI":"10.3390\/ijms23116260","volume":"23","author":"AF AlAsmari","year":"2022","unstructured":"AlAsmari AF, Alghamdi A, Ali N, Almeaikl MA, Hakami HM, Alyousef MK, et al. Venetoclax induces cardiotoxicity through modulation of oxidative-stress-mediated cardiac inflammation and apoptosis via NF-\u03baB and BCL-2 pathway. Int J Mol Sci. 2022;23:6260. https:\/\/doi.org\/10.3390\/ijms23116260.","journal-title":"Int J Mol Sci"},{"key":"1481_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2020.100529","volume":"28","author":"Y Sato-Okabayashi","year":"2020","unstructured":"Sato-Okabayashi Y, Isoda K, Heissig B, Kadoguchi T, Akita K, Kitamura K, et al. Low-dose oral cyclophosphamide therapy reduces atherosclerosis progression by decreasing inflammatory cells in a murine model of atherosclerosis. IJC Heart Vasc. 2020;28:100529. https:\/\/doi.org\/10.1016\/j.ijcha.2020.100529.","journal-title":"IJC Heart Vasc"},{"key":"1481_CR144","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/s44161-024-00507-y","volume":"3","author":"AL Bayer","year":"2024","unstructured":"Bayer AL, Zambrano MA, Smolgovsky S, Robbe ZL, Ariza A, Kaur K, et al. Cytotoxic T cells drive doxorubicin-induced cardiac fibrosis and systolic dysfunction. Nat Cardiovasc Res. 2024;3:970\u201386. https:\/\/doi.org\/10.1038\/s44161-024-00507-y.","journal-title":"Nat Cardiovasc Res"},{"key":"1481_CR145","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1093\/cvr\/cvae208","volume":"120","author":"J Zhang","year":"2024","unstructured":"Zhang J, Ding W, Yin Z, Liu S, Zhao M, Xu Y, et al. Interleukin-12p40 deficiency attenuates myocardial ferroptosis in doxorubicin-induced chronic cardiomyopathy by inhibiting Th17 differentiation and interleukin-17A production. Cardiovasc Res. 2024;120:2117\u201333. https:\/\/doi.org\/10.1093\/cvr\/cvae208.","journal-title":"Cardiovasc Res"},{"key":"1481_CR146","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/ajcp\/100.2.158","volume":"100","author":"PB Gaudin","year":"1993","unstructured":"Gaudin PB, Hruban RH, Beschorner WE, Kasper EK, Olson JL, Baughman KL, et al. Myocarditis associated with doxorubicin cardiotoxicity. Am J Clin Pathol. 1993;100:158\u201363. https:\/\/doi.org\/10.1093\/ajcp\/100.2.158.","journal-title":"Am J Clin Pathol"},{"key":"1481_CR147","doi-asserted-by":"publisher","unstructured":"White-Gilbertson S, Hua Y, Liu B. The role of endoplasmic reticulum stress in maintaining and targeting multiple myeloma: a double-edged sword of adaptation and apoptosis. Front Genet. 2013;4. https:\/\/doi.org\/10.3389\/fgene.2013.00109","DOI":"10.3389\/fgene.2013.00109"},{"key":"1481_CR148","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/cncr.32601","volume":"126","author":"B Fakhri","year":"2020","unstructured":"Fakhri B, Fiala MA, Shah N, Vij R, Wildes TM. Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-medicare database. Cancer. 2020;126:808\u201313. https:\/\/doi.org\/10.1002\/cncr.32601.","journal-title":"Cancer"},{"key":"1481_CR149","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1111\/bph.16391","volume":"181","author":"P Efentakis","year":"2024","unstructured":"Efentakis P, Varela A, Lamprou S, Papanagnou E, Chatzistefanou M, Christodoulou A, et al. Implications and hidden toxicity of cardiometabolic syndrome and early-stage heart failure in carfilzomib-induced cardiotoxicity. Br J Pharmacol. 2024;181:2964\u201390. https:\/\/doi.org\/10.1111\/bph.16391.","journal-title":"Br J Pharmacol"},{"key":"1481_CR150","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.645122","volume":"8","author":"M Tantawy","year":"2021","unstructured":"Tantawy M, Chekka LM, Huang Y, Garrett TJ, Singh S, Shah CP, et al. Lactate dehydrogenase B and pyruvate oxidation pathway associated with carfilzomib-related cardiotoxicity in multiple myeloma patients: result of a multi-omics integrative analysis. Front Cardiovasc Med. 2021;8:645122. https:\/\/doi.org\/10.3389\/fcvm.2021.645122.","journal-title":"Front Cardiovasc Med"},{"key":"1481_CR151","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/bju.14083","volume":"121","author":"D Abt","year":"2018","unstructured":"Abt D, Besse A, Sedlarikova L, Kraus M, Bader J, Silzle T, et al. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir. BJU Int. 2018;121:600\u20139. https:\/\/doi.org\/10.1111\/bju.14083.","journal-title":"BJU Int"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01481-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01481-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01481-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:47:29Z","timestamp":1785451649000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01481-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":151,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1481"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01481-3","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NS is an inventor on patent applications through The University of Texas MD Anderson Cancer Center and reports research funding from Panbela Therapeutics. KP reports consulting from AbbVie, AstraZeneca, Bristol Myers Squibb, Celgene, Johnson & Johnson, Kite, Legend Biotech, Merck, Pfizer, Novartis, Sanofi, and Regeneron; has served on advisory boards for Sanofi and Novartis; and reports research support from Bristol Myers Squibb, Celgene, Kite, Oricel, and Indapta. NP reports research support from CPRIT RP200670, NIH\/NCI 1P01CA261669-01, and Kiniksa Pharmaceuticals. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"129"}}